While autologous therapies are mainstream in blood cancers, experts warn against overhyping allogeneic and in vivo approaches ...

The advent of chimeric antigen receptor (CAR)-T cell therapy has marked the onset of a very promising option to treat solid tumors after its remarkable ...

During a live event, Matthew Lunning, DO, discussed key factors that determine whether patients should receive CAR T-cell ...

Two recent studies show the novel therapy works in people with multiple myeloma, but researchers are trying to minimize side ...

Kyverna plans to submit mivocabtagene autoleucel to the FDA for approval in the first half of 2026. If approved, it would be ...

An in vivo chimeric antigen receptor T-cell therapy administered without lymphodepletion exhibited activity among patients with advanced multiple myeloma, according to findings presented at ASH Annual ...

Cell therapy company Link Cell Therapies is launching with $60 million and a mission to develop potent CAR-T therapies that ...

The company intends to file a U.S. application in the first half of 2026 following positive study results in a condition ...

Kyverna Therapeutics looks all the more likely to win the first FDA approval for a CAR-T therapy in an autoimmune disease after a registrational trial showed “highly statistically significant” ...

The Food and Drug Administration (FDA) has approved Breyanzi ® (lisocabtagene maraleucel; liso-cel) for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) ...